Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome

Abstract Metabolic syndrome (MetS) is a multi-factorial disorder including central obesity (CO), insulin resistance, hyperglycemia, dyslipidemia and hypertension which increases the risk of diabetes mellitus and cardiovascular diseases. CO is considered as an essential component of MetS according to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Angus P. Yu, Felix N. Ugwu, Bjorn T. Tam, Paul H. Lee, Vicki Ma, Simon Pang, Angel S. Chow, Kenneth K. Cheng, Christopher W. Lai, Cesar S. Wong, Parco M. Siu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3f2eda47a2514e728e03aea01f260127
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3f2eda47a2514e728e03aea01f260127
record_format	dspace
spelling	oai:doaj.org-article:3f2eda47a2514e728e03aea01f2601272021-12-02T17:04:37ZObestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome10.1038/s41598-020-62271-w2045-2322https://doaj.org/article/3f2eda47a2514e728e03aea01f2601272020-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-62271-whttps://doaj.org/toc/2045-2322Abstract Metabolic syndrome (MetS) is a multi-factorial disorder including central obesity (CO), insulin resistance, hyperglycemia, dyslipidemia and hypertension which increases the risk of diabetes mellitus and cardiovascular diseases. CO is considered as an essential component of MetS according to International Diabetes Federation (IDF), which may further modulate distinct signalling pathways compared with the other four MetS risk factors. Given that ghrelin signalling and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis regulates energy balance and metabolic homeostasis, this study examined the changes in various ghrelin products and circulating hormones in response to the interaction between CO and other MetS components including blood pressure, fasting blood glucose, triglycerides, and high-density lipoprotein cholesterol in 133 Hong Kong Chinese adults. Circulating obestatin and GH were increased and reduced, respectively, by either CO or the other 4-risk factor cluster. These changes were further augmented by the presence of all MetS risk factors. However, changes of ghrelin levels were not mediated by CO but the other MetS risk factors. Our findings suggest that CO does not predict all the dysregulation of signalling pathways in individuals with MetS. Although CO and other MetS may share common signalling targets (i.e., obestatin and GH), CO does not contribute to the perturbation of ghrelin signalling.Angus P. YuFelix N. UgwuBjorn T. TamPaul H. LeeVicki MaSimon PangAngel S. ChowKenneth K. ChengChristopher W. LaiCesar S. WongParco M. SiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Angus P. Yu Felix N. Ugwu Bjorn T. Tam Paul H. Lee Vicki Ma Simon Pang Angel S. Chow Kenneth K. Cheng Christopher W. Lai Cesar S. Wong Parco M. Siu Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
description	Abstract Metabolic syndrome (MetS) is a multi-factorial disorder including central obesity (CO), insulin resistance, hyperglycemia, dyslipidemia and hypertension which increases the risk of diabetes mellitus and cardiovascular diseases. CO is considered as an essential component of MetS according to International Diabetes Federation (IDF), which may further modulate distinct signalling pathways compared with the other four MetS risk factors. Given that ghrelin signalling and the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis regulates energy balance and metabolic homeostasis, this study examined the changes in various ghrelin products and circulating hormones in response to the interaction between CO and other MetS components including blood pressure, fasting blood glucose, triglycerides, and high-density lipoprotein cholesterol in 133 Hong Kong Chinese adults. Circulating obestatin and GH were increased and reduced, respectively, by either CO or the other 4-risk factor cluster. These changes were further augmented by the presence of all MetS risk factors. However, changes of ghrelin levels were not mediated by CO but the other MetS risk factors. Our findings suggest that CO does not predict all the dysregulation of signalling pathways in individuals with MetS. Although CO and other MetS may share common signalling targets (i.e., obestatin and GH), CO does not contribute to the perturbation of ghrelin signalling.
format	article
author	Angus P. Yu Felix N. Ugwu Bjorn T. Tam Paul H. Lee Vicki Ma Simon Pang Angel S. Chow Kenneth K. Cheng Christopher W. Lai Cesar S. Wong Parco M. Siu
author_facet	Angus P. Yu Felix N. Ugwu Bjorn T. Tam Paul H. Lee Vicki Ma Simon Pang Angel S. Chow Kenneth K. Cheng Christopher W. Lai Cesar S. Wong Parco M. Siu
author_sort	Angus P. Yu
title	Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
title_short	Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
title_full	Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
title_fullStr	Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
title_full_unstemmed	Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
title_sort	obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/3f2eda47a2514e728e03aea01f260127
work_keys_str_mv	AT anguspyu obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT felixnugwu obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT bjornttam obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT paulhlee obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT vickima obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT simonpang obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT angelschow obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT kennethkcheng obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT christopherwlai obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT cesarswong obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome AT parcomsiu obestatinandgrowthhormonerevealtheinteractionofcentralobesityandothercardiometabolicriskfactorsofmetabolicsyndrome
_version_	1718381843783352320

Obestatin and growth hormone reveal the interaction of central obesity and other cardiometabolic risk factors of metabolic syndrome

Ejemplares similares